Puddu A - Search Results

1

Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome.

Montecucco F, Bertolotto M, Vuilleumier N, Franciosi U, Puddu A, Minetti S, Delrio A, Quercioli A, Bergamini E, Ottonello L, Pende A, Lenglet S, Pelli G, Mach F, Dallegri F, Viviani GL. Montecucco F, et al. Among authors: puddu a. Am J Physiol Endocrinol Metab. 2011 Apr;300(4):E681-90. doi: 10.1152/ajpendo.00527.2010. Epub 2011 Jan 25. Am J Physiol Endocrinol Metab. 2011. PMID: 21266669 Free article. Clinical Trial.

2

Rat serum improves rat pseudoislet formation and insulin gene expression.

Lione L, Puddu A, Pedemonte A, Viviani GL. Lione L, et al. Among authors: puddu a. Boll Soc Ital Biol Sper. 2001 Jan-Mar;77(1-3):13-9. Boll Soc Ital Biol Sper. 2001. PMID: 11512494

3

Advanced glycation end-products affect transcription factors regulating insulin gene expression.

Puddu A, Storace D, Odetti P, Viviani GL. Puddu A, et al. Biochem Biophys Res Commun. 2010 Apr 23;395(1):122-5. doi: 10.1016/j.bbrc.2010.03.152. Epub 2010 Mar 29. Biochem Biophys Res Commun. 2010. PMID: 20353756

4

Advanced glycation endproducts and diabetes. Beyond vascular complications.

Puddu A, Viviani GL. Puddu A, et al. Endocr Metab Immune Disord Drug Targets. 2011 Jun;11(2):132-40. doi: 10.2174/187153011795564115. Endocr Metab Immune Disord Drug Targets. 2011. PMID: 21476962 Review.

5

Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15.

Puddu A, Sanguineti R, Durante A, Viviani GL. Puddu A, et al. Regul Pept. 2012 Aug 20;177(1-3):79-84. doi: 10.1016/j.regpep.2012.05.089. Epub 2012 May 12. Regul Pept. 2012. PMID: 22587907

6

Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization.

Puddu A, Sanguineti R, Durante A, Nicolò M, Viviani GL. Puddu A, et al. Mol Vis. 2012;18:2509-17. Epub 2012 Oct 11. Mol Vis. 2012. PMID: 23112566 Free PMC article.

7

An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes.

Puddu A, Mach F, Nencioni A, Viviani GL, Montecucco F. Puddu A, et al. Mediators Inflamm. 2013;2013:591056. doi: 10.1155/2013/591056. Epub 2013 Jan 10. Mediators Inflamm. 2013. PMID: 23365488 Free PMC article.

8

Glucagon-like peptide-1 triggers protective pathways in pancreatic beta-cells exposed to glycated serum.

Puddu A, Sanguineti R, Durante A, Nencioni A, Mach F, Montecucco F, Viviani GL. Puddu A, et al. Mediators Inflamm. 2013;2013:317120. doi: 10.1155/2013/317120. Epub 2013 Apr 29. Mediators Inflamm. 2013. PMID: 23737644 Free PMC article.

9

Update on the protective molecular pathways improving pancreatic beta-cell dysfunction.

Puddu A, Sanguineti R, Mach F, Dallegri F, Viviani GL, Montecucco F. Puddu A, et al. Mediators Inflamm. 2013;2013:750540. doi: 10.1155/2013/750540. Epub 2013 May 2. Mediators Inflamm. 2013. PMID: 23737653 Free PMC article. Review.

10

Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 (GLP-1).

Puddu A, Sanguineti R, Montecucco F, Viviani GL. Puddu A, et al. Mediators Inflamm. 2013;2013:975032. doi: 10.1155/2013/975032. Epub 2013 Nov 6. Mediators Inflamm. 2013. PMID: 24307763 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters